Cargando…
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
SIMPLE SUMMARY: Immune checkpoint blockers are important immunotherapies for the treatment of patients with Hodgkin lymphoma. The resistance mechanisms of these immunotherapies remain unknown. This pilot study aims to decipher the resistance mechanisms of immunotherapies in Hodgkin lymphoma. The mai...
Autores principales: | Michot, Jean-Marie, Mouraud, Severine, Adam, Julien, Lazarovici, Julien, Bigenwald, Camille, Rigaud, Charlotte, Tselikas, Lambros, Dartigues, Peggy, Danu, Alina, Bigorgne, Amélie, Minard, Veronique, Ghez, David, Marabelle, Aurélien, Zitvogel, Laurence, Ribrag, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582920/ https://www.ncbi.nlm.nih.gov/pubmed/34771650 http://dx.doi.org/10.3390/cancers13215487 |
Ejemplares similares
-
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
por: Michot, Jean-Marie, et al.
Publicado: (2021) -
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma
por: Quivoron, Cyril, et al.
Publicado: (2022) -
Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas
por: Saleh, Khalil, et al.
Publicado: (2020) -
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
por: Rouanne, Mathieu, et al.
Publicado: (2022) -
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies
por: Bigenwald, Camille, et al.
Publicado: (2023)